^
Association details:
| Biomarker: | KEAP1 mutation + KRAS wild-type |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EP08.01-043 - Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
Published date:
07/12/2022
Excerpt:
In this multicenter retrospective analysis, clinicopathologic and genomic data were collected from patients with metastatic NSCLC....A total of 1200 patients treated with first-line pembrolizumab in combination with platinum-doublet chemotherapy were identified....Among KRAS wt tumors, KEAP1 mutations were associated with shorter mPFS (HR: 1.37, P=0.01) and mOS (HR: 1.61, P<0.001) to chemoimmunotherapy...KEAP1 mutation held a significant association with shorter mPFS (HR: 1.70, P<0.001) and mOS (HR: 2.04, P<0.001) among KRAS wt cases in multivariable model...only KEAP1 mutations are associated with impaired outcomes among KRAS wt.
Secondary therapy:
Chemotherapy
